Stratos Wealth Partners’s Celldex Therapeutics CLDX Stock Holding History

Stratos Wealth Partners’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-25,000	Closed	-$56K	–	933
2019 Q4	$56K	Hold	25,000	–	–	﹤0.01%	967
2019 Q3	$53K	Hold	25,000	–	–	﹤0.01%	938
2019 Q2	$67K	Buy	25,000 +5,000	+25%	+$17K	﹤0.01%	934
2019 Q1	$98K	Buy	20,000 +3,333	+20%	+$17.5K	﹤0.01%	901
2018 Q4	$49K	Buy	16,667 +16,000	+2,399%	+$78.6K	﹤0.01%	854
2018 Q3	$5K	Buy	+667	New	+$4.67K	﹤0.01%	2434
2018 Q2	–	Sell	-67	Closed	-$2K	–	1231
2018 Q1	$2K	Buy	+67	New	+$2.6K	﹤0.01%	2831

Other funds holding CLDX

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CAM

Cresset Asset Management Chicago, Illinois $23.1B AUM 27.04% 1-Year Est. Return

TCMG

TSP Capital Management Group Summit, New Jersey $410M AUM 71.81% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Stratos Wealth Partners's CLDX Position: Q1 2020 in Review

Stratos Wealth Partners sold out of Celldex Therapeutics (CLDX) in Q1 2020, closing a stake of 25,000 shares — an estimated $56K sold.

Stratos Wealth Partners first reported a position in CLDX in Q1 2018 and held it in 7 quarters. The position peaked at $98K in Q1 2019. 45 funds tracked by Wall St. Rank hold CLDX as of Q1 2020.

Stratos Wealth Partners reported no remaining Celldex Therapeutics position as of Q1 2020 after selling out during the quarter.
Stratos Wealth Partners sold 25,000 Celldex Therapeutics shares in Q1 2020, an estimated $56K.
Stratos Wealth Partners first reported a position in Celldex Therapeutics in Q1 2018 and held it in 7 quarters.
Stratos Wealth Partners's Celldex Therapeutics position peaked at $98K in Q1 2019.
45 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2020.

Based on Stratos Wealth Partners's 13F filing for Q1 2020, filed 4 May 2020.